Evelo Biosciences (NASDAQ:EVLO – Get Free Report) is expected to be issuing its resultson Tuesday, November 17th. Analysts expect Evelo Biosciences to post earnings of ($10.1333) per share for the quarter.
Evelo Biosciences Stock Down 100.0%
The firm has a market cap of $2,000.00, a P/E ratio of -0.00 and a beta of 1.34. Evelo Biosciences has a 1-year low of $0.00 and a 1-year high of $0.00.
About Evelo Biosciences
Evelo Biosciences, Inc was a clinical-stage biotechnology company focused on developing orally administered medicines designed to modulate the immune system through the small intestinal axis. The company’s approach centered on “monoclonal microbials,” which are defined strains of bacteria intended to produce targeted effects on immune and inflammatory pathways.
Evelo’s development programs included EDP1815, an investigational treatment studied in inflammatory diseases such as atopic dermatitis and psoriasis, and EDP2939, an investigational program intended to address immune-mediated conditions.
See Also
- Five stocks we like better than Evelo Biosciences
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
